Chronic sciatica. Diseases of the musculoskeletal system and connective tissue
Conditions
Interventions
Intervention 1: First intervention group: Chronic sciatica patients use topically 10 drops(half a cc) of henna oil(in sesame oil base) on the low back and unilateral painful area from gluteal to middl
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with chronic unilateral sciatica pain (lumbar radiculopathy in this study defined chronic back pain that spread to a leg. Pain described as sharp, burning with numbness and/or tingling.) For at least 3 months and more Age 18 to 65 years Pain score of 1 or more on visual analog scale (VAS) of 0 to 10 Willingness of patients to participate in the study Patients without communication problems (vision, hearing, speaking and understanding) Pain not attributable to malignancy, inflammatory arthritis such as rheumatoid arthritis, or blood diseases and coagulation and infectious diseases Patients without congenital spinal abnormalities, bone fractures, scoliosis, kyphosis and spondylosis Patients are not candidate for surgery No history of surgery in the lower back No history of alcohol and narcotic abuse Body mass index(BMI) between 18.5 to 34.9
Exclusion criteria
Exclusion criteria: Pregnancy or lactation Severe allergy to any of the medications used in the study Severe side effects Unwillingness to continue participating in the study No use of oils more than twice in a row Occurring acute illness or accident during the study Patients with G6PD Aggravation of pain Use of other complementary and alternative therapies Use of analgesics out of the study during the study Cauda equine syndrome symptoms include numbness and weakness in both legs, pain in the anal area, perineal numbness, paralysis of the sphincters Symptoms require further investigation during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain intensity. Timepoint: At the beginning of the study (before the intervention) and 7, 14 and 28 days after the start of the study. Method of measurement: Visual Analogue Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Diclofenac tablets taken daily. Timepoint: during study. Method of measurement: Number.;Disability. Timepoint: Before the start of the study and 4 weeks after the start of the study(the end of the study). Method of measurement: Oswestry disability questionnaire.;Quality of Life. Timepoint: Before the start of the study and 4 weeks after the start of the study(the end of the study). Method of measurement: The Short form health survey 36 questionnaire (SF-36).;Skin side effects. Timepoint: Days 3, 7, 14 and 28 days after the start of the study. Method of measurement: Form of skin side effects based on CTCAE(Common Terminology Criteria for Adverse) version 5. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNarges Lavari
Tehran University of Medical Sciences
Outcome results
None listed